Table 2 Key information of the SELECT trial [49]

Class &

Cardiovascular (CV) outcomes

HR (95% CI)

p-value‡

Primary efficacy endpoint

Composite of 3P-MACE: CV death, nonfatal MI, or nonfatal stroke

0.80 (0.72 to 0.90)

< 0.001

Confirmatory secondary efficacy endpoints

CV death

0.85 (0.71 to 1.01)

0.07

Composite of HF: CV death, HHF, or urgent medical visit for HF

0.82 (0.71 to 0.96)

Death from any cause

0.81 (0.71 to 0.93)

Adverse events

Event rate (%) active vs. placebo group

p-value

Serious adverse events

33.4 vs. 36.4

< 0.001

Cardiac disorders

11.5 vs. 13.5

< 0.001

Infections and infestations

7.1 vs. 8.4

0.001

Nervous system disorders

5.0 vs. 5.6

0.08

Surgical and medical procedures

4.9 vs. 6.2

< 0.001

Neoplasms benign, malignant, and unspecified

4.6 vs. 4.6

0.94

Gastrointestinal disorders

3.9 vs. 3.7

0.48

Adverse events leading to treatment discontinuation

16.6 vs. 8.2

< 0.001

Gastrointestinal disorders

10.0 vs. 2.0

< 0.001

Nervous system disorders

1.4 vs. 1.0

0.03

Metabolism and nutrition disorders

1.2 vs. 0.3

< 0.001

General disorders and administration-site conditions

1.2 vs. 0.5

< 0.001

Neoplasms benign, malignant, and unspecified

0.9 vs. 1.2

0.07

Infections and infestations

0.9 vs. 1.0

0.47

Other adverse events of interest

Gallbladder-related disorders

2.8 vs. 2.3

0.04

Acute kidney failure

1.9 vs. 2.3

0.13

Acute pancreatitis

0.2 vs. 0.3

0.28